Half-Life of Ibogaine

half-life of ibogaine

The half-life of ibogaine is the central organizing concept for understanding exposure, risk, and timing. In clinical and observational human datasets, ibogaine shows an elimination half-life of roughly 4–8 hours, with faster clearance in an extensive metabolizer and slower in a poor metabolizer due to CYP2D6 activity differences. Noribogaine, the active metabolite, typically has an elimination half-life of about 28–49 hours in humans, which supports effects that persist for days and shapes the QTc interval risk window as concentrations fall. Because ibogaine is a psychoactive alkaloid derived from Tabernanthe iboga, its pharmacokinetics and the longer noribogaine tail determine operational choices such as monitoring duration, washout period planning, and drug-drug interactions to avoid.

Readers seeking basic background can reference the general overview of ibogaine as a psychoactive alkaloid at the Ibogaine encyclopedia entry, and a pharmacology-focused slide deck outlining metabolism and exposure on the Ibogaine pharmacology summary. This page emphasizes practical pharmacokinetics, elimination half-life ranges, and cardiac considerations rather than therapeutic claims.

Checklist assessment

1) Define exposure windows

Confirm ibogaine elimination half-life ~4–8 h; noribogaine ~28–49 h.
Map tmax and cmax to set initial ECG timing.
Plan a washout period that covers the noribogaine tail.

2) Metabolism & interactions

Evaluate CYP2D6 status; account for phenoconversion.
Screen for enzyme inhibitors/inducers and QT-prolongers.
Consider hepatic impairment and renal impairment impacts.

3) Monitoring & testing

Establish ECG schedule through 1–3 days post-dose.
Use LC‑MS/MS if a detection window must be documented.
Correct electrolytes, especially potassium and magnesium.

Explanation cards

what half-life means in pharmacokinetics

In pharmacokinetics, half-life is the time for plasma levels to fall by 50% during the terminal phase of a concentration-time curve. For ibogaine, the distribution phase can be distinct from the terminal phase because the compound is lipophilic, with a large apparent volume of distribution and high protein binding. Half-life depends on clearance and volume of distribution, and it is shaped by metabolism, including first-pass metabolism and subsequent enzymatic steps. Because elimination half-life is one observable summary of many processes, interindividual variability arises from weight and BMI, age and sex, hepatic impairment, renal impairment for the metabolite, and drug-drug interactions that modify enzyme activity.

Close-up conceptual diagram illustrating pharmacokinetic half-life and terminal phase decline for ibogaine.

ibogaine vs noribogaine half-life

Ibogaine commonly reaches peak plasma levels (tmax) in about 1–2 hours after oral dosing, followed by a biphasic elimination as distribution and terminal phases unfold. Noribogaine reaches its tmax later, about 2–4 hours, and displays an elimination half-life near 28–49 hours. This contrast produces different exposure and accumulation patterns, with noribogaine serving as an active metabolite that prolongs therapeutic effect duration while extending the window for QT prolongation. The area under the curve for ibogaine can increase 2–3× in a poor metabolizer, and noribogaine exposure shifts in time, a reminder that half-life variability is a product of metabolism and distribution dynamics rather than dosing alone.

factors that influence ibogaine elimination

metabolism pathways and enzymes

Ibogaine is primarily converted to noribogaine by O-demethylation via CYP2D6, with contributions from CYP3A4 and CYP2C9 to alternative routes. Noribogaine is then cleared mainly through glucuronidation, predominantly UGT2B7, enabling renal and biliary excretion. A poor metabolizer for CYP2D6 experiences higher ibogaine plasma levels and a longer elimination half-life, while an extensive metabolizer clears the parent compound faster and generates the metabolite earlier. Phenoconversion caused by inflammation or inhibitors can reduce functional CYP2D6 activity, altering clearance and exposure-response even when genotype suggests normal metabolism. These mechanisms underlie the two-compartment model behavior and can produce nonlinear kinetics at high doses.

distribution, protein binding, and volume of distribution

Because ibogaine is lipophilic, it exhibits a large volume of distribution that can exceed 10 L/kg in human modeling, indicating extensive intercompartmental distribution. High protein binding for both ibogaine and noribogaine (>80%) supports a prolonged terminal phase as bound drug slowly dissociates. Adipose tissue serves as a modest depot; lipid partitioning lengthens tail exposure and contributes to interindividual variability. These properties influence tmax, observed cmax, and the shape of the concentration-time curve, as early distribution gives way to first-order elimination during the terminal phase. The outcome is a measurable difference between the parent’s shorter half-life and the metabolite’s longer tail.

time to peak, duration, and accumulation

Typical oral dosing yields an ibogaine tmax within 1–2 hours and a noribogaine tmax around 2–4 hours. The acute central nervous system experience may last 24–36 hours, while the noribogaine tail supports multi-day effects. Repeated exposure risks accumulation, especially if dosing recurs before a sufficient washout period. While steady state is not a usual goal for ibogaine, the concept clarifies how bioavailability, clearance, and volume of distribution interact: higher bioavailability or reduced clearance increases the area under the curve, can intensify dose dependence, and may enhance QTc effects as concentrations overlap. Monitoring must therefore track both the parent and the active metabolite.

drug interactions and contraindications

Strong CYP2D6 or CYP3A4 enzyme inhibitors can increase ibogaine exposure, prolonging the effective half-life and shifting the concentration-time curve. Examples include paroxetine, fluoxetine, and ketoconazole, whereas enzyme inducers like rifampin reduce exposure and can truncate the metabolite tail. Drug-drug interactions that also prolong QTc, such as methadone or haloperidol, elevate arrhythmia risk by compounding hERG channel blockade. Because ibogaine and noribogaine both affect the hERG channel, small changes in the area under the curve may translate into exposure-response shifts in QT prolongation, especially under electrolyte imbalance. Clinical decisions should include baseline screening, medication reconciliation, and a washout period tailored to noribogaine’s longer elimination half-life.

Key interacting agents to reassess: paroxetine, fluoxetine, ketoconazole, rifampin, methadone, haloperidol, quinidine, clarithromycin—and any concurrent QT-prolonging or enzyme-modulating therapies.

cardiac safety and qtc considerations

hERG, QT prolongation, and timing

Ibogaine and noribogaine inhibit the hERG channel, producing concentration-dependent QT prolongation that peaks as levels rise and can persist as the metabolite declines. Documented median QTc increases are around 10–30 ms within 12–24 hours post-dose, returning toward baseline over 1–3 days as concentrations fall. Because QT prolongation tracks the metabolite’s tail, the highest arrhythmia risk overlaps the day following dosing, particularly with hypokalemia, hypomagnesemia, or interacting agents. This reality connects directly to elimination half-life and motivates serial ECGs across the 24–72 hour window.

arrhythmia risk modifiers

Arrhythmia risk increases with low electrolytes, especially potassium and magnesium; underlying heart disease; congenital long QT; and concurrent QT-prolonging medications. Clinicians should correct electrolytes, avoid unnecessary QT-prolongers like methadone or haloperidol, and consider phenoconversion that suppresses CYP2D6. The therapeutic window is narrow around peak exposure; careful dose timing, nutrition planning, and avoidance of a high-fat meal if the food effect is a concern can mitigate abrupt cmax spikes. Safety monitoring integrates ECG at anticipated peaks, and spot checks during the noribogaine tail guide discharge decisions.

operationalizing ECG strategy

Baseline screening, serial ECGs at 2–6 hours for early changes, and again within 12–24 hours where QTc rise often peaks provide a coherent plan. Because the noribogaine elimination half-life controls lingering QTc interval effects, extended observation over 24–72 hours aligns with exposure-response dynamics. Consider dose dependence by correlating cmax and area under the curve with observed QTc movements, and document any nonlinear kinetics when metabolism is inhibited. These steps keep safety monitoring proportional to the metabolite’s persistence.

testing, detection windows, and washout

Standard immunoassay urine testing does not target ibogaine or noribogaine; laboratories use LC-MS/MS for confirmation. With sensitive assays, ibogaine may be detectable in blood for roughly 12–24 hours, and noribogaine can be detected in urine for about 5–7 days post-exposure. Hair testing can extend the detection window much longer for documentation purposes. When planning a washout period, align pharmacokinetics with clinical goals: a full noribogaine tail suggests multiple days before reintroducing QT-prolonging medications. Plasma levels, especially in a poor metabolizer, can remain clinically relevant beyond the parent’s terminal phase, so timing should reflect metabolite persistence and any impaired clearance.

Recommended path

Anchor the plan to elimination half-life metrics and adjust for interindividual variability. Emphasize testing modalities, ECG timing, and drug reconciliation to prevent avoidable exposure-response spikes.

LC‑MS/MS when documentation of exposure is needed.
Schedule ECGs across 24–72 h to capture QTc dynamics.
Ensure electrolytes are in range before and after dosing.

legal and regulatory context

In the United States, ibogaine is classified under legal status as Schedule I and it currently lacks FDA approval, though global regulatory approaches differ. Some countries have allowed highly controlled prescription pathways; for instance, New Zealand instituted limited medical oversight in 2009. Because legal status influences access, oversight, and safety monitoring standards, pharmacokinetic literacy becomes critical: the longer noribogaine tail and QTc risks necessitate protocols that align with elimination half-life and clearance realities regardless of jurisdictional stance.

QTc monitoring aligns with noribogaine’s terminal phase.

t½ parent ~4–8 h, metabolite ~28–49 h.

Testing requires LC‑MS/MS to define the detection window.

evidence from human studies

Human data from clinical trials and observational studies converge on key pharmacokinetic parameters: an ibogaine elimination half-life of approximately 4–8 hours, noribogaine near 28–49 hours, tmax 1–2 hours for the parent and 2–4 hours for the metabolite, and a biphasic decline consistent with a two-compartment model. These studies also document QT prolongation that correlates with exposure: dose dependence emerges in concentration-time curves where higher cmax and larger area under the curve elevate QTc, especially when metabolism is inhibited. Collectively, clinical trials, together with observational studies, show interindividual variability that is driven by metabolism steps, enzyme activity, and distribution properties.

Because ibogaine and noribogaine interact with the NMDA receptor, sigma-1 receptor, and kappa opioid receptor among other targets, pharmacodynamics intertwines with pharmacokinetics. The active metabolite supports longer therapeutic effect duration and shapes the safety window. Several lines of human data indicate QTc changes returning toward baseline within 1–3 days post-dose, reinforcing the link between noribogaine’s terminal phase and practical monitoring. These findings underscore the importance of safety monitoring with ECG during the metabolite tail and avoidance of medications that extend QTc while the metabolite persists.

metabolism, models, and variability

Metabolism centers on CYP2D6-driven O-demethylation to noribogaine, with ancillary roles for CYP3A4 and CYP2C9, followed by UGT2B7-mediated glucuronidation. First-pass metabolism and bioavailability interact to shape early plasma levels, the observed cmax, and ultimately exposure-response relationships. A poor metabolizer accumulates higher parent levels and experiences a longer elimination half-life and greater area under the curve; an extensive metabolizer clears faster and transitions sooner to metabolite-dominant exposure. These kinetic distinctions mirror a two-compartment model, where a distribution phase yields to a terminal phase that obeys first-order elimination. Nonlinear kinetics may appear when enzyme saturation or inhibition complicates clearance.

Interindividual variability is common. Weight and BMI alter distribution volume; lipophilic properties and adipose tissue depots extend the terminal tail; age and sex can subtly affect clearance; hepatic impairment slows parent and metabolite metabolism; renal impairment influences metabolite elimination more strongly than parent drug. Phenoconversion—enzyme suppression from inflammation or an inhibitor—can shift a person with otherwise normal genotype into functional poor metabolism, altering half-life and the detection window. By incorporating these parameters into planning, clinicians can time ECGs around expected tmax and the noribogaine tail, while documenting exposure with LC-MS/MS when necessary.

operational implications

timelines and washout

Operational plans should anchor to the noribogaine elimination half-life when setting a washout period. A practical design includes baseline screening, ECG within a few hours of peak, and repeat ECG across 24–72 hours to track QTc normalization. When interacting drugs are present, extend observation and repeat electrolytes. Documenting a detection window is best done with LC-MS/MS rather than routine urine testing, and hair testing is an option when longer-term confirmation is needed.

genetics and clearance

CYP2D6 genotype predicts much of the clearance pattern: extensive metabolizers typically show faster parent drug clearance and earlier metabolite rise, while a poor metabolizer shows delayed conversion, elevated ibogaine plasma levels, and a longer parent half-life. Phenoconversion may temporarily reduce CYP2D6 activity and mimic poor metabolism. These dynamics should shape dose timing and monitoring intensity.

interaction stewardship

Enzyme inhibitors such as paroxetine, fluoxetine, ketoconazole, and clarithromycin increase exposure; enzyme inducers like rifampin reduce it; quinidine strongly inhibits CYP2D6. Parallel avoidance of QT-prolongers like methadone or haloperidol mitigates additive QTc risk. Matching the pharmacokinetics with a medication review prevents unplanned accumulation and exposure spikes.

frequently asked questions

How long is the half-life of ibogaine in humans?

The ibogaine elimination half-life is roughly 4–8 hours in humans, shorter in an extensive metabolizer and longer in a poor metabolizer due to CYP2D6 activity. Peak plasma levels often occur at a tmax of about 1–2 hours, after which the concentration-time curve transitions into a terminal phase characterized by first-order elimination.

How long does noribogaine stay in the body?

Noribogaine typically displays an elimination half-life of approximately 28–49 hours, with a tmax near 2–4 hours and a longer tail that can keep QTc vulnerability present for 1–3 days. Sensitive LC-MS/MS assays may detect noribogaine in urine for 5–7 days following exposure.

What factors can lengthen or shorten ibogaine’s half-life?

Clearance is shaped by metabolism pathways such as O-demethylation via CYP2D6, contributions from CYP3A4 and CYP2C9, and subsequent glucuronidation by UGT2B7. Enzyme inhibitors and inducers, hepatic impairment, renal impairment for the metabolite, weight and BMI, lipophilic distribution into adipose tissue, and phenoconversion can all influence half-life variability.

How do CYP2D6 genetic differences affect clearance?

An extensive metabolizer clears the parent compound faster, generating earlier noribogaine exposure, while a poor metabolizer has elevated plasma levels of ibogaine, a longer parent elimination half-life, and delayed metabolite rise. This alters area under the curve and can intensify dose dependence and QTc sensitivity during the terminal phase.

How long does QTc risk persist after ibogaine exposure?

Median QTc increases on the order of 10–30 ms have been observed within 12–24 hours, generally normalizing over 1–3 days as noribogaine levels fall. Because hERG channel effects are shared by both parent and metabolite, the noribogaine tail extends the safety window for ECG monitoring, particularly if electrolytes are low or interacting medications are present.